Long noncoding RNA lnc-IL7R (also referred to as CAPSL divergent transcript) (lnc-IL7R, CAPSL-DT)

CAPSL divergent transcript, commonly known as lnc-IL7R or lnc-IL7R-1, is a long noncoding RNA that is upregulated in human cells in response to LPS stimulation through TLR2 and TLR4 (myeloid differentiation pathways). It is nuclear-enriched and overlaps with the 3' UTR of the IL7R gene, but functions independently of the IL7R protein-coding transcript. Knockdown of lnc-IL7R leads to enhanced expression of several pro-inflammatory mediators, suggesting that it serves as a negative regulator of inflammatory gene expression by modulating chromatin structure (specifically H3K27 trimethylation) at promoter regions of these mediators. CAPSL-DT does not encode a protein and has no classic enzyme, transport, or receptor activity, yet its regulation of inflammatory pathways may make it relevant in research on immune and inflammatory diseases. Although "CAPSL divergent transcript" and "lnc-IL7R-1" are valid lncRNA designations, they are not typical targets for drugs and should not be conflated with classic receptors or enzymes when curating target lists for drug development.

Other names

CAPSL divergent transcriptCAPSL-DTlnc-IL7R-1lnc-IL7R

Currently, no known drugs directly target CAPSL-DT/lnc-IL7R. However, if a drug or therapeutic agent were ever found to affect CAPSL divergent transcript, its mechanism would likely involve modulation of lnc-IL7R transcription, stability, or epigenetic interactions. Mechanistically, CAPSL-DT (lnc-IL7R) acts by antagonizing histone modifications that silence inflammatory genes, thereby dampening inflammatory responses in the nucleus. It is upregulated in response to LPS (lipopolysaccharide) via TLR2 and TLR4 signaling in a MyD88-dependent manner, distinct from the regulation of the protein-coding IL7R gene.